

## CURRICULUM VITAE

**Date of Revision:** 3/1/2019

**Name:** Kasia J Lipska, M.D., M.H.S.

**Current Appointment:** Assistant Professor, Department of Internal Medicine,  
Section of Endocrinology and Metabolism

**School:** Yale University School of Medicine

### Education:

B.S. Molecular Biochemistry and Biophysics, Yale University, 1997  
M.D. Harvard Medical School, 2003  
M.H.Sc. Yale University School of Medicine, 2011

### Career/Academic Appointments:

2002-2003 Research Investigator, Sree Chitra Tirunal Institute, Trivandrum, India  
2003-2006 Intern and Resident, Department of Internal Medicine, Brigham and Women's Hospital,  
Boston, MA  
2006-2007 Internal Medicine Attending, Northern Navajo Medical Center in Shiprock, New Mexico  
(Indian Health Service)  
2007-2009 Fellow, Section of Endocrinology and Metabolism, Yale-New Haven Hospital New  
Haven, CT  
2007-2011 Clinical Fellow, Veterans Administration Specialty Clinic in General Endocrinology,  
West Haven VA, CT  
2009-2011 Robert Wood Johnson Clinical Scholar, Department of Internal Medicine, Yale  
University School of Medicine, New Haven, CT  
2011-2012 Fogarty International Clinical Research Fellow, Public Health Foundation of India, New  
Delhi and Trivandrum  
2012-2014 Instructor in Medicine, Section of Endocrinology, Department of Medicine, Yale School  
of Medicine, New Haven, CT  
2013-present Clinical Investigator, Yale-New Haven Hospital Center for Outcomes Research and  
Evaluation (CORE), New Haven, CT  
2014-present Assistant Professor of Medicine, Yale University School of Medicine, New Haven, CT

### Board Certification:

American Board of Internal Medicine, 2007  
American Board of Endocrinology and Metabolism, 2009

### Professional Honors & Recognition:

#### A) International/National/Regional

2013 ADA-ASP Young Investigator Career Development Award in Geriatric Endocrinology  
2013 Grants for Early Medical/Surgical Specialists' Transition to Aging (GEMSSTAR) Award  
2013 Pepper Research Career Development Core Scholar Award  
2013 American Diabetes Association Young Investigator Travel Award  
2013 NIH Loan Repayment Program  
2012 National Institute on Aging Summer Institute

2011 Fogarty International Clinical Research Fellow and Fulbright Scholar to India  
2002 Paul Dudley White & Andrew Sellard Traveling Fellow

**B) University**

2013 Yale Center for Clinical Investigation (YCCI) Scholar Award  
1997 *Cum laude* diploma, Yale University  
1997 Distinction in the Major, Molecular Biochemistry and Biophysics, Yale University  
1997 Phi Beta Kappa, Yale University

**Grant/Clinical Trials History:**

**Current Grants**

Agency: NIH/NIA

I.D.# K23 AG048359 (Lipska)  
Title: Predicting Severe Hypoglycemia among Older Adults with Diabetes  
P.I.: Kasia Lipska, MD  
Role: PI  
Percent effort: 71.35%  
Direct cost per year: \$154,695  
Total cost for project period: \$720,847  
Project Period: 9/1/2014-6/30/2019

Agency: NIH/NIDDK

I.D.# R01 DK103721 (Karter)  
Title: Severe Hypoglycemia: Ascertainment, Surveillance and Pharmacovigilance  
P.I.: Andrew Karter, PhD  
Role: Sub Award PI  
Percent effort: 5%  
Direct cost per year: \$10,425  
Project Period: 3/1/2018-7/31/2019

Agency: NIH/NIDDK

I.D.# P30DK045735 (Sherwin)  
Title: Hypoglycemia in Nursing Home Residents with Diabetes – How Often, How Severe, and Who Is at Risk?  
P.I.: Robert Sherwin, MD  
Role: Pilot PI  
Percent effort: 10%  
Direct cost per year: \$32,000  
Total cost for project period: \$64,000  
Project Period: 2/1/2016-1/31/2019

Agency: NIH/NIA

I.D.# R21 AG061427 (Lipska, Montori)  
Title: QBSafe: A novel approach to care for older, complex adults with type 2 diabetes.  
Percent effort: 12%  
Total cost for project period: \$262,730  
Project period: 1/15/2019-1/14/2021

**Past Grants**

Agency: NIH/NIA

I.D.# P30 AG21342 (Gill)

Title: Hospital Admissions for Diabetes Complications – Understanding Recent Trends and Etiology

P.I.: Thomas Gill, MD

Role: Research Career Development Core Scholar

Percent effort: 0%

Direct cost per year: \$45,000

Total cost for project period: \$149,850

Project Period: 7/1/2013-5/31/2018

Agency: NIH/NIA

I.D.# R03 AG13006 (Lipska)

Title: Hypoglycemia in Older Adults with Diabetes: From Better Understanding of Adverse Events Toward Personalized Care

P.I.: Kasia Lipska, MD

Role: PI

Percent effort: 10%

Direct cost per year: \$74,547

Total cost for project period: \$124,121

Project Period: 7/1/2013-6/30/2014

Agency: NIH

I.D.# KL2 RR024138 (Sherwin)

Title: Treatment-Related Determinants of Severe Hypoglycemia in Type 2 Diabetes

P.I.: Robert Sherwin, MD

Role: YCCI Scholar

Percent effort: 75%

Direct cost per year: \$118,954

Total cost for project period: \$118,954

Project Period: 7/1/2013-6/30/2014

**Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:**

**International/National**

- 2019 Victor and Betty Rosenfeld Memorial Lecture, Providence St Vincent's and Providence Portland Medical Center, Medical Grand Rounds, Portland, Oregon, "The Insulin Racket – Why Is A Century-Old Drug Still So Expensive and What Can We Do About It?"
- 2019 Project ECHO, Albuquerque, New Mexico, "Diabetes Management on a Budget."
- 2019 University of Massachusetts, Endocrine Grand Rounds, Worcester, Massachusetts, "The Insulin Cost Scandal."
- 2018 Naomi Berrie Diabetes Center, Columbia University Medical Center, New York, New York, "Hypoglycemia During Treatment of Type 2 Diabetes."
- 2018 American Diabetes Association Research Symposium, Washington D.C., "Use of Real-World Data for Surveillance and Monitoring."
- 2018 Albert Einstein College of Medicine, Internal Medicine Interest Group Seminar, Bronx, New York, "Break Up the Insulin Racket."
- 2018 American Geriatrics Society 2018 Annual Scientific Meeting, Orlando, Florida, "Hypoglycemia During Treatment of Diabetes."

- 2018 University of Pennsylvania School of Medicine, Center for Clinical Epidemiology & Biostatistics Seminar Series, Philadelphia, Pennsylvania, “Hypoglycemia in Patients with Type 2 Diabetes Mellitus.”
- 2017 American Diabetes Association 77<sup>th</sup> Scientific Sessions, San Diego, California, “Dealing with the Rising Costs of Insulin—An Active Dialogue.”
- 2017 99<sup>th</sup> Meeting of the Endocrine Society, Orlando, Florida, Meet-the-Professor Symposium, “Goals of Diabetes Care in the Oldest of the Old.”
- 2016 Massachusetts General Hospital, Endocrine Grand Rounds, Boston, Massachusetts, “Lilacs, Lactate, Lies, and Labels.”
- 2016 Columbia University Medical Center, Division of General Medicine, New York, New York, Joint Division Conference, “Type 2 Diabetes in Older Patients.”
- 2016 Mayo Clinic, Knowledge and Evaluation Research Unit, Rochester, Minnesota, “When Diabetes Treatment Goes Too Far.”
- 2016 American Diabetes Association 76<sup>th</sup> Scientific Sessions, New Orleans, Louisiana, “Clinical Controversies—Use of Metformin in Patients with Reduced Kidney Function—Current Data.”
- 2015 Kaiser Permanente, Division of Research, Oakland, California, “When Diabetes Treatment Goes Too Far.”
- 2015 American Diabetes Association 75<sup>th</sup> Scientific Sessions, Boston, Massachusetts, “Trends in Health Care Utilization.”
- 2014 US Investigators' Symposium on Global Non-Communicable Diseases Research, Emory Conference Center, Atlanta, Georgia, “Why is global health important for young researchers?”
- 2012 Diabetes Disparities: Innovations in Identifying and Addressing Them in Medicaid Managed Care Plans, Pre-conference Workshop - MHPA Annual Meeting, Washington D.C., Workshop Keynote, “2012 American Diabetes Association Guidelines and Recommendations: Key Changes Impacting Patient Care.”
- 2012 Sree Chitra Tirunal Institute for Medical Sciences and Technology, India, “Hyperglycemia, insulin resistance, and diabetes – Implications for stroke outcomes.”
- 2011 Diabetes and the Challenge of Resource Poor Countries, Massachusetts General Hospital Center for Global Health seminar, panelist, Boston, Massachusetts.
- 2010 Heart Disease and Pregnancy Symposium, Pennsylvania Hospital, Philadelphia, Pennsylvania, “Diabetes and pregnancy.”

### **Regional**

- 2018 Greenwich Hospital Grand Rounds, Greenwich, CT, “The Insulin Cost Scandal.”
- 2018 St. Mary’s Hospital Grand Rounds, Waterbury, CT, “Update on Diabetes Management.”
- 2017 Griffin Hospital Grand Rounds, Derby, CT, “Update on Diabetes Management.”
- 2017 Waterbury Hospital Grand Rounds, Waterbury, CT, “Diabetes Among Older Adults.”
- 2014 St. Mary’s Hospital Grand Rounds, Waterbury, CT, “Cardiovascular Risk Reduction: The Holy Grail of Anti-Hyperglycemic Therapy.”
- 2012 Greenwich Hospital Grand Rounds, Greenwich, CT, “Diabetes Clinical Guidelines.”
- 2011 China-Fuwai Hospital Visit to Yale, Center for Outcomes Research and Evaluation, “Diabetes Outcomes Research.”

### **Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale:**

#### **International/National**

- 2016 American Diabetes Association's 76th Scientific Sessions, New Orleans, Louisiana, "Trends in Medication Use, Glycemic Control, and Rates of Severe Hypoglycemia, 2006 to 2013."
- 2014 American Geriatrics Society Annual Meeting, Orlando, Florida, "National trends in admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999-2011."

## Professional Service

### Peer Review Groups/Grant Study Sections:

- 2016-present Member, Clinical Study Section, Research Grant Review Committee, American Diabetes Association Research Programs
- 2017 Ad hoc reviewer for Diabetes UK, Harry Keen Intermediate Clinical Fellowship
- 2017 Member, Special Emphasis Panel for FOA "Community Characteristics Associated with Geographic Disparities in Diabetes and Cardiometabolic Health," National Center for Chronic Disease Prevention and Health Promotion, CDC
- 2014-2016 Ad Hoc Member, American Diabetes Association Scientific Sessions Abstract Review Committee
- 2014 Ad Hoc grant reviewer for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U.S.-India Bilateral Collaborative Research Partnerships (CRP) on Diabetes Research (R21)
- 2013 Ad Hoc grant reviewer for the targeted American Diabetes Association and Lilly Clinical Research Award: Diabetes Care in Older Adults
- 2010 Ad Hoc Member, Society for General Internal Medicine (SGIM) Abstract Review Committee

### Journal Service:

#### Editor/Associate Editor

2012-2014 Editorial Board, *Journal of Clinical Endocrinology & Metabolism*

#### Reviewer

2009-present Reviewer for *New England Journal of Medicine*, *Circulation*, *PLoS*, *JAMA*, *JAMA Internal Medicine*, *Diabetes Care*, *Journal of Clinical Endocrinology & Metabolism*, *Journal of General Internal Medicine*, *Endocrine Practice*, *Journal of the American College of Cardiology*, *Diabetes and Vascular Disease Research*, *Hospital Practice*

## Professional Service for Professional Organizations:

### *Hypoglycemia Coalition of the Atlantic Quality Improvement Network*

2015-2016 Steering Committee Member

### *American Heart Association*

2013-2017 Committee Member, Diabetes Committee for the Nutrition, Physical Activity and Metabolism (NPAM) Council

### *American Diabetes Association*

2007-present Member

### *Meeting Planning/Participation*

2017-2018 Member of the ADA Scientific Sessions Planning Committee: Epidemiology

- 2016 Member of the ADA Scientific Sessions Planning Subcommittees: Epidemiology and Hypoglycemia
- 2016 Member of the Paul Beeson Meeting Planning Committee
- 2015 Member of the ADA Scientific Sessions Planning Subcommittee: Epidemiology
- 2014 Member, Organizing Committee, US Investigators' Symposium on Global Non-Communicable Diseases Research, Emory Conference Center, Atlanta, GA

**Yale University Service:**

***University Committees***

- 2016-present Founding Member, Yale Network for Global Non-Communicable Diseases

***Medical School Committees***

- 2012-2015 Tutor for the Pre-Clinical Clerkship Program, Yale University School of Medicine
- 2014-2015 PA Thesis Readers Committee, Yale Physician Associate Program
- 2010 Journal Club Leader for Physician Assistant Students, Yale University School of Medicine

***Hospital Boards & Committees***

- 2013-present Committee Member, Yale-New Haven Hospital System Clinical Integration Diabetes Workgroup
- 2016-2017 Member, Healthier Greater New Haven Partnership, Diabetes Workgroup

**Public Service:**

- 2019 Invited guest, National Public Radio, On Point: "Insulin Has Become Unaffordable. Patients Are Dying In Their Efforts To Ration Doses."
- 2016 Op-ed contributor: Break up the insulin racket. *The New York Times*, Opinion Pages, published February 20, 2016.
- 2015 Op-ed contributor: When diabetes treatment goes too far. *The New York Times*, Opinion Pages, published January 12, 2015.
- 2014 Op-ed contributor: The global diabetes epidemic. *The New York Times*, Sunday Review Opinion, published April 25, 2014.
- 2011 Invited Guest, National Public Radio, Where We Live: "Understanding Diabetes."

**Bibliography:**

**Peer-Reviewed Original Research**

1. **Lipska K**, Sylaja PN, Sarma PS, Thankappan KR, Kutty VR, Vasani RS, Radhakrishnan K. (2007) Risk factors for acute ischaemic stroke in young adults in South India. *Journal of Neurology, Neurosurgery, and Psychiatry* 78: 959-63.
2. **Lipska KJ**, Wang Y, Kosiborod M, Masoudi FA, Havranek EP, Krumholz HM, Inzucchi SE. (2010) The discontinuation of anti-hyperglycemic therapy and clinical outcomes after acute myocardial infarction in older patients with diabetes. *Circulation: Cardiovascular Quality and Outcomes*, 3: 236-242.
3. **Lipska KJ**, De Rekeneire N, Van Ness PH, Johnson KC, Kanaya A, Koster A, Strotmeyer ES, Goodpaster BH, Harris T, Gill TM, Inzucchi SE. (2010) Identifying dysglycemic states in older adults: Implications of the emerging use of hemoglobin A1c. *Journal of Clinical Endocrinology & Metabolism*, 95(12): 5289-95.

4. **Lipska KJ**, Venkitachalam L, Gosch K, Kovatchev B, Van den Berghe G, Meyfroidt G, Jones P, Inzucchi SE, Spertus JA, DeVries JH, Kosiborod M. (2012) Glucose variability and mortality in patients hospitalized with acute myocardial infarction. *Circulation: Cardiovascular Quality and Outcomes* 5(4):550-7.
5. Lovig KO, Horwitz L, **Lipska K**, Kosiborod M, Krumholz HM, Inzucchi SE. (2012) Discontinuation of antihyperglycemic therapy after acute myocardial infarction: Medical necessity or medical error? *Jt Comm J Qual Patient Saf.* 38(9):403-7.
6. Sankar UV, **Lipska K**, Mini GK, Sarma PS, Thankappan KR. (2013) The adherence to medications in diabetic patients in rural Kerala, India. *Asia Pac J Public Health*, Feb 14, Epub ahead of print.
7. Arnold SV, **Lipska KJ**, Li Y, Goyal A, Maddox TM, McGuire DK, Spertus JA, Kosiborod M. (2013) The reliability and prognosis of in-hospital diagnosis of metabolic syndrome in the setting of acute myocardial infarction. *J Am Coll Cardiol.* 62(8):704-8.
8. Venkitachalam L, McGuire DK, Gosch K, **Lipska K**, Inzucchi SE, Lind M, Goyal A, Spertus JA, Masoudi FA, Jones PG, Kosiborod M. (2013) Temporal trends and hospital variation in the management of severe hyperglycemia among patients with acute myocardial infarction in the United States. *Am Heart J* 166(2):315-324.
9. **Lipska KJ**, Warton EM, Huang ES, Moffet HH, Inzucchi SE, Krumholz HM, Karter AJ. (2013) HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. *Diabetes Care* 36(11):3535-42.
10. **Lipska KJ**, Inzucchi SE, Van Ness PH, Gill TM, Kanaya A, Strotmeyer ES, Koster A, Johnson KC, Goodpaster BH, Harris T, De Rekeneire N, for the Health ABC Study. (2013) Elevated HbA1c and fasting plasma glucose in predicting diabetes incidence among older adults: are two better than one? *Diabetes Care* 36(12):3923-9.
11. Arnold SV, Spertus JA, **Lipska KJ**, Tang F, Goyal A, McGuire DK, Cresci S, Maddox TM, Kosiborod M. (2014) Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study. *European Journal of Preventive Cardiology*, Epub ahead of print
12. **Lipska KJ**, Ross JS, Wang Y, Inzucchi SE, Mingos K, Karter AJ, Huang ES, Desai MM, Gill TM, Krumholz HM. (2014) National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. *JAMA Internal Medicine* 74(7):1116-24.
13. **Lipska KJ**, Ross JS, Van Houten HK, Beran D, Yudkin JS, Shah ND. (2014) Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 to 2010. *JAMA* 311(22):2331-3.
14. Arnold SV, Spertus JA, **Lipska KJ**, Lanfear DE, Tang F, Grodzinsky A, McGuire DK, Gore MO, Goyal A, Maddox TM, Kosiborod M. (2014) Type of  $\beta$ -blocker use among patients with versus without diabetes after myocardial infarction. *Am Heart J.* 168(3):273-279.
15. Arnold SV, **Lipska KJ**, Li Y, McGuire DK, Goyal A, Spertus JA, Kosiborod M. (2014) Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. *Am Heart J.* 168(4):466-470.
16. Clements MA, Lind M, Raman S, Patton SR, **Lipska KJ**, Fridlington AG, Tang F, Jones PG, Wu Y, Spertus JA, Kosiborod M. (2014) Age at diagnosis predicts deterioration in glycaemic control among children and adolescents with type 1 diabetes. *BMJ Open Diabetes Res Care.* 2(1):e000039.
17. Arnold SV, **Lipska KJ**, Inzucchi SE, Li Y, Jones PG, McGuire DK, Goyal A, Stolker JM, Lind M, Spertus JA, Kosiborod M. (2014) The reliability of in-hospital diagnoses of diabetes mellitus in the setting of acute myocardial infarction. *BMJ Open Diabetes Res Care.* 2(1):e000046.
18. **Lipska KJ**, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. (2015) Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. *JAMA Intern Med.* 175(3):356-62.

19. Arnold SV, Stolker JM, **Lipska KJ**, Jones PG, Spertus JA, McGuire DK, Inzucchi SE, Goyal A, Maddox TM, Lind M, Gumber D, Shore S, Kosiborod M. (2015) Recognition of incident diabetes mellitus during an acute myocardial infarction. *Circ Cardiovasc Qual Outcomes*. 8(3):260-7.
20. Bonner B, Pillai R, Sarma PS, **Lipska KJ**, Pandian J, Sylaja PN. (2015) Factors predictive of return to work after stroke in patients with mild-moderate disability in India. *Eur J Neurol*. 23(3):548-53.
21. Spatz ES, **Lipska KJ**, Dai Y, Bao H, Lin Z, Parzynski CS, Altaf FK, Joyce EK, Montague JA, Ross JS, Bernheim SM, Krumholz HM, Drye EE. (2016) Risk-standardized acute admission rates among patients with diabetes and heart failure as a measure of quality of Accountable Care Organizations: Rationale, methods, and early results. *Med Care*. 54(5):528-37.
22. Arnold SV, Spertus JA, Jones PG, McGuire DK, Lipska KJ, Xu Y, Stolker JM, Goyal A, Kosiborod M. (2016) Predicting adverse outcomes after acute myocardial infarction among patients with diabetes mellitus. *Circ Cardiovasc Qual Outcomes*. 9(4):372-9.
23. McCoy RG, **Lipska KJ**, Yao X, Ross JS, Montori VM, Shah ND. (2016) Intensive treatment and severe hypoglycemia among adults with type 2 diabetes. *JAMA Intern Med*. 176(7):969-78.
24. Espeland MA, **Lipska K**, Miller ME, Rushing J, Cohen RA, Verghese J, McDermott MM, King AC, Strotmeyer ES, Blair SN, Pahor M, Reid K, Demons J, Kritchevsky SB; LIFE Study Investigators. (2016) Effects of physical activity intervention on physical and cognitive function in sedentary adults with and without diabetes. *J Gerontol A Biol Sci Med Sci*. 1;72(6):861-866.
25. Rodriguez-Gutierrez R, Ospina NS, McCoy RG, **Lipska KJ**, Shah ND, Montori VM; Hypoglycemia as a Quality Measure in Diabetes Study Group. (2016) Inclusion of hypoglycemia in clinical practice guidelines and performance measures in the care of patients with diabetes. *JAMA Intern Med*. 176(11):1714-1716.
26. **Lipska KJ**, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. (2016) Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. *Diabetes Care*. 40(4):468-475.
27. Karter AJ, **Lipska KJ**, O'Connor PJ, Liu JY, Moffet HH, Schroeder EB, Lawrence JM, Nichols GA, Newton KM, Pathak RD, Desai J, Waitzfelder B, Butler MG, Thomas A, Steiner JF; SUPREME-DM Study Group (2017) High rates of severe hypoglycemia among African American patients with diabetes: the surveillance, prevention, and Management of Diabetes Mellitus (SUPREME-DM) network. *J Diabetes Complications*. 31(5):869-873.
28. Moffet HH, Warton EM, Siegel L, Sporer K, **Lipska KJ**, Karter AJ. (2017) Hypoglycemia patients and transport by EMS in Alameda county, 2013-15. *Prehosp Emerg Care*. 21(6):767-772.
29. McCoy RG, **Lipska KJ**, Herrin J, Jeffery MM, Krumholz HM, Shah ND. (2017) Hospital readmissions among commercially insured and medicare advantage beneficiaries with diabetes and the impact of severe hypoglycemic and hyperglycemic events. *J Gen Intern Med*. 32(10):1097-1105.
30. Karter AJ, Warton EM, **Lipska KJ**, Ralston JD, Moffet HH, Jackson GG, Huang ES, Miller DR. (2017) Development and validation of a tool to identify patients with type 2 diabetes at high risk of hypoglycemia-related emergency department or hospital use. *JAMA Intern Med*. 177(10):1461-1470.
31. Drye EE, Altaf FK, **Lipska KJ**, Spatz ES, Montague JA, Bao H, Parzynski CS, Ross JS, Bernheim SM, Krumholz HM, Lin Z. (2018) Defining multiple chronic conditions for quality measurement. *Med Care*. 56(2):193-201.
32. MacNeil Vroomen JL, Han L, Monin JK, **Lipska KJ**, Allore HG. (2018) Diabetes, heart disease, and dementia: National estimates of functional disability trajectories. *J Am Geriatr Soc*. 66(4):766-772.



33. Arnold SV, **Lipska** KJ, Wang J, Seman L, Mehta SN, Kosiborod M. (2018) Use of intensive glycemic management in older adults with diabetes mellitus. *J Am Geriatr Soc*. Epub ahead of print.
34. Karter AJ, Moffet HH, Liu JY, **Lipska** KJ. (2018) Surveillance of hypoglycemia – Limitations of emergency department and hospital utilization data. *JAMA Intern Med*. Epub ahead of print.
35. McCoy RG, Herrin J, **Lipska** KJ, Shah ND. (2018) Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes. *J Diabetes Complications*. 32(7):693-701.
36. **Lipska** KJ, Parker MM, Moffet HH, Huang ES, Karter AJ. (2018) Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes. *JAMA*. 320(1):53-62.
37. Benchetrit L, Zimmerman C, Bao H, Dharmarajan K, Altaf F, Herrin J, Lin Z, Krumholz HM, Drye EE, **Lipska** KJ, Spatz ES. (2019) Admission diagnoses among patients with heart failure: Variation by ACO performance on a measure of risk-standardized acute admission rates. *Am Heart J*. 207:19-26.
38. Basu S, Yudkin JS, Kehlenbrink S, Davies JI, Wild SH, **Lipska** KJ, Sussman JB, Beran D. (2019) Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis. *Lancet Diabetes Endocrinol*. 7(1):25-33.
39. Herkert D, Vijayakumar P, Luo J, Schwartz JI, Rabin TL, DeFilippo E, **Lipska** KJ. (2019) Cost-Related Insulin Underuse Among Patients With Diabetes. *JAMA Intern Med*. 179(1):112-114.
40. Ross JS, Rohde S, Sangaralingham L, Brito JP, Choi L, Dutcher SK, Graham DJ, Jenkins MR, **Lipska** KJ, Mendoza M, Qiang Y, Wang Z, Wu Y, Yao X, Shah ND. (2019) Generic and Brand-Name Thyroid Hormone Drug Use among Commercially-Insured and Medicare Beneficiaries, 2007-2016. *J Clin Endocrinol Metab*. Epub ahead of print.
41. Karter AJ, Warton EM, Moffet HH, Ralston JD, Huang ES, Miller DR, **Lipska** KJ. (2019) Revalidation of the Hypoglycemia Risk Stratification Tool Using ICD-10 Codes. *Diabetes Care*. Epub ahead of print.

### Chapters, Books, and Reviews

42. **Lipska** KJ, Bailey C, Inzucchi SE. (2011) Use of metformin in the setting of mild-moderate renal insufficiency. *Diabetes Care* 34(6):1431-7.
43. **Lipska** KJ, Kosiborod M. (2012) Management of blood glucose in patients with acute coronary syndromes. *Rev Cardiovasc Med*, 13(2-3):e77-88.
44. Inzucchi SE, **Lipska** KJ, Mayo H, Bailey CJ, McGuire DK. (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. *JAMA* 312(24):2668-75.
45. Inzucchi SE, **Lipska** KJ. (2014) “Effect of glucose management on coronary heart disease risk in patients with diabetes” in: *Diabetes in Cardiovascular Disease: A Companion to Braunwald’s Heart Disease*. McGuire D, Marx N, Eds., Philadelphia: Elsevier Inc, Chapter 13, pp.155-170.
46. **Lipska** KJ, Krumholz H, Soones T, Lee SJ. (2016) Polypharmacy in the aging patient: A review of glycemic control in older adults with type 2 diabetes. *JAMA*. 315(10):1034-45.
47. Beran D, Ewen M, **Lipska** K, Hirsch IB, Yudkin JS. (2018) Availability and affordability of essential medicines: Implications for global diabetes treatment. *Curr Diab Rep*. 18(8):48.
48. Flory JH, **Lipska** KJ. (2019) Metformin in 2018. *JAMA*. In press.

### Invited Editorials and Commentaries

49. **Lipska** KJ, Ross JS. (2011) Switching from rosiglitazone; Thinking outside the class. *JAMA* 305(8):820-1.

50. **Lipska KJ**, Kosiborod M. (2011) Hypoglycemia and adverse outcomes: Marker or mediator? *Rev Cardiovasc Med.* 12(3):132-135.
51. Yudkin JS, **Lipska KJ**, Montori V. (2011) The idolatry of the surrogate. *BMJ* 343:d7995.
52. **Lipska KJ**, Montori VM. (2013) Glucose control in older adults with diabetes – More harm than good? *JAMA Intern Med.* 173(14):1306-7.
53. Gionfriddo MR, McCoy RG, **Lipska KJ**. (2013) The 2013 American Association of Clinical Endocrinologists' diabetes mellitus management recommendations: Improvements needed. *JAMA Intern Med.* 174(2):179-80.
54. **Lipska KJ**, Krumholz HM. (2014) Comparing Diabetes Medications: Where Do We Set the Bar? *JAMA Intern Med* 174(3):317-8.
55. **Lipska KJ**. (2014) Improving safety of diabetes mellitus management. *JAMA Intern Med.* 174(10):1612-3.
56. Jaacks LM, Ali MK, Bartlett J, Bloomfield GS, Checkley W, Gaziano TA, Heimbarger DC, Kishore SP, Kohler RE, **Lipska KJ**, Manders O, Ngaruiya C, Peck R, Pena MB, Watkins DA, Siegel KR, Narayan KM. (2015) Global noncommunicable disease research: Opportunities and challenges. *Ann Intern Med.* 163(9):712-4.
57. Rodriguez-Gutierrez R, **Lipska KJ**, McCoy RG, Ospina NS, Ting HH, Montori VM; Hypoglycemia as a Quality Measure in Diabetes Study Group. (2016) Hypoglycemia as an indicator of good diabetes care. *BMJ.* 352:i1084.
58. Peter P, **Lipska K**. (2016) The rising cost of diabetes care in the USA. *Lancet Diabetes Endocrinol.* 4(6):479-80.
59. **Lipska KJ**, Flory JH, Hennessy S, Inzucchi SE. (2016) Citizen petition to the US Food and Drug Administration to Change Prescribing Guidelines: The metformin experience. *Circulation.* 134(18):1405-1408.
60. **Lipska KJ**. (2017) Metformin use in patients with historical contraindications. *Annals Intern Med.* 166(3):225-226.
61. **Lipska KJ**, Krumholz HM. (2017) Is Hemoglobin A1c the Right Outcome for Studies of Diabetes? *JAMA.* 317(10):1017-1018.
62. Luo J, Kesselheim AS, Greene J, **Lipska KJ**. (2017) Strategies to improve the affordability of insulin in the USA. *Lancet Diabetes Endocrinol.* 5(3):158-159.
63. **Lipska KJ**, Hirsch IB, Riddle MC. (2017) Human Insulin for Type 2 Diabetes: An Effective, Less Expensive Option. *JAMA.* 318(1):23-24.
64. Goldstein JN, McCrary M, **Lipska KJ**. (2018) Is the Over-the-Counter Availability of Human Insulin in the United States Good or Bad? *JAMA Intern Med.* 178(9):1157-1158.
65. **Lipska, KJ**. (2019) Insulin Analogues for Type 2 Diabetes. *JAMA.* 321(4):350-351.

#### Case Reports, Technical Notes, Letters

66. **Lipska KJ**, Inzucchi SE, Kosiborod M, Krumholz HM. (2009) Intensive glucose control and cardiovascular outcomes. *Lancet.* 374(9689):522-3.
67. **Lipska K**, Inzucchi SE. (2009) Cardiovascular risk-benefit ratio of thiazolidinediones. *Curr Cardiovasc Risk Rep* 3(1):42-50.
68. Yudkin JS, Montori VM, **Lipska KJ**, Gale EA. (2012) ADDITION-Europe and the case for diabetes screening. *Lancet.* 379(9813):313.
69. Yudkin JS, **Lipska KJ**. (2012) Hard end points are needed for intensive glycaemic control in patients with type 2 diabetes. *BMJ.* 344:e708.
70. Gionfriddo MR, McCoy RG, **Lipska KJ**. (2014) AACE response to viewpoint of December 9, 2013 – reply. *JAMA Intern Med.* 174(5):827-8.

71. Rodriguez-Gutierrez R, **Lipska KJ**, McCoy RG. (2016) Intensive glyceic control in type 2 diabetes mellitus – A balancing act of latent benefit and avoidable harm: A teachable moment. *JAMA Intern Med.* 176(3):300-1.
72. **Lipska KJ**. (2016) JAMA Patient Page. Diabetes in Older People. *JAMA.* 316(3):362.
73. **Lipska KJ**, Montori VM. (2016) ACP Journal Club. In type 1 diabetes, intensive insulin therapy for 6.5 y reduced mortality at 27 y compared with usual care. *Ann Intern Med.* 162(10):JC12.
74. McCoy R, **Lipska K**. (2016) Physicians frequently fail to de-intensify treatment in older patients with diabetes and very low haemoglobin A1c or blood pressure. *Evid Based Med.* 21(4):158.